Company Search:
Advanced Search
Sponsored Links
Eurofins-Cerep SA Company Snapshot
Eurofins-Cerep SA operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Eurofins-Cerep SA with three other companies in this sector in France: Adocia SAS (2017 sales of 19.47 million Euro [US$22.02 million] of which 100% was Regenerative Medicine), Cellectis SA (29.60 million Euro [US$33.48 million] of which 106% was Therapeutics), and Innate Pharma S.A. (32.63 million Euro [US$36.91 million] of which 100% was Licensing Revenue).

Sales Analysis. During the year ended December of 2017, sales at Eurofins-Cerep SA were 24.41 million Euro (US$27.61 million). This is an increase of 4.1% versus 2016, when the company's sales were 23.44 million Euro. This was the third consecutive year of growth at Eurofins-Cerep SA.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Eurofins-Cerep SA
  Stock Performance Chart for Eurofins-Cerep SA
  Stock Data: Recent Stock Performance:
  Current Price (2/13/2019): 6,250.00
(Figures in Euro)
1 Week n/a   13 Weeks -6.0%  
4 Weeks 2.5%   52 Weeks n/a  
Eurofins-Cerep SA Key Data:
  Ticker: ALECR Country: France
  Exchanges: PAR Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2017 Sales 24,410,000
(Year Ending Jan 2018).
Employees: 178
  Currency: Euro Market Cap: 31,525,000
  Fiscal Yr Ends: December Shares Outstanding: 5,044
  Share Type: Actions Ordinaires Closely Held Shares: 4,831
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.